Price alert —
Sign in to get a one-time email the moment ABSI crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · ABSI
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -13767.0% | -14347.0% |
| 2025-12-31 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -4548.0% | -5560.3% |
| 2025-09-30 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -7594.2% | -7977.2% |
| 2025-06-30 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -5155.0% | -5293.9% |
| 2025-03-31 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -2234.6% | -2351.9% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare ABSI vs peers
Line ABSI up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with ABSI
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-07 | -0.19 | -0.20 | +4.6% | +2.6% |
| 2026-03-24 | -0.23 | -0.17 | -32.5% | -3.0% |
| 2025-11-12 | -0.20 | -0.21 | +2.5% | -22.4% |
| 2025-08-12 | -0.24 | -0.21 | -15.1% | +5.0% |
| 2025-05-13 | -0.21 | -0.22 | +6.0% | -1.7% |
| 2025-03-18 | -0.25 | -0.22 | -11.7% | -3.2% |
| 2024-11-12 | -0.24 | -0.19 | -23.1% | -13.7% |
| 2024-08-14 | -0.22 | -0.18 | -20.0% | +11.0% |
| 2024-05-14 | -0.22 | -0.20 | -11.9% | -0.1% |
| 2024-03-21 | -0.25 | -0.22 | -12.6% | -6.2% |
| 2023-11-14 | -0.24 | -0.22 | -7.5% | +0.0% |
| 2023-08-14 | -0.22 | -0.24 | +6.7% | -7.3% |
| 2023-05-15 | -0.26 | -0.24 | -9.5% | -8.6% |
| 2023-03-30 | -0.21 | -0.25 | +15.3% | +4.2% |
| 2022-11-09 | -0.30 | -0.28 | -7.8% | -3.5% |
| 2022-08-11 | -0.32 | -0.31 | -4.6% | -0.2% |
| 2022-05-11 | -0.33 | -0.28 | -17.0% | +1.7% |
| 2022-03-22 | -0.28 | -0.24 | -16.7% | +0.7% |
| 2021-11-09 | -0.33 | -0.17 | -94.1% | -9.4% |
| 2021-09-07 | -0.75 | -0.87 | +13.7% | -17.2% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| ABSI ★ | $1B | — | -13.3 | 765.3 | -10.1 | 7.5 | — | -81.8% | — | -2.95% |
| LLY | $1,040B | 41.5 | 26.0 | — | 30.0 | 33.4 | 82.8% | 55.5% | 169.9% | 0.88% |
| UNH | $393B | 32.6 | 19.3 | 0.9 | 18.1 | 3.8 | 19.5% | 0.4% | 61.5% | 5.79% |
| JNJ | $616B | 29.7 | 19.9 | 6.3 | 18.3 | 7.6 | 68.1% | 6.6% | -1.0% | — |
| MRK | $316B | 36.1 | 13.3 | — | 12.0 | 6.9 | 76.7% | 4.9% | — | 4.44% |
| ABBV | $452B | 124.9 | 15.7 | 7.2 | 17.2 | -68.0 | 72.0% | 12.4% | -46.2% | 4.60% |
| PFE | $142B | 19.1 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.69% |
| TMO | $194B | 28.7 | 19.1 | — | 20.8 | 3.7 | 40.9% | 6.2% | 11.3% | 2.85% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 54.22%
| Holder | Shares | % out |
|---|---|---|
| FMR, LLC | 22,550,997 | 14.46% |
| ARK Investment Management, LLC | 13,726,169 | 8.80% |
| Blackrock Inc. | 11,255,194 | 7.22% |
| Redmile Group, LLC | 8,253,316 | 5.29% |
| State Street Corporation | 7,324,858 | 4.70% |
| Vanguard Capital Management LLC | 5,886,640 | 3.78% |
| Advanced Micro Devices Inc | 5,714,285 | 3.67% |
| Geode Capital Management, LLC | 3,343,068 | 2.14% |
| Woodline Partners LP | 3,300,169 | 2.12% |
| Ameriprise Financial, Inc. | 3,180,141 | 2.04% |
Insider activity · 90d
14 buys / 0 sells · ratio 14.0 · Finnhub
- Szela Mary T BUY 21,300 @ $11.54
- McClain Sean F 8,655,555 @ $10.07
- Szela Mary T BUY 33,200
- Szela Mary T BUY 8,400
- MCGINNIS KAREN K BUY 39,800
- MCGINNIS KAREN K BUY 48,420
- Pangalos Menelas N BUY 39,800
- Pangalos Menelas N BUY 242,408
- VAN HOUTEN FRANS BUY 39,800
- VAN HOUTEN FRANS BUY 73,420
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-06 | FORM 4 | view · |
| 4 | 2026-06-26 | FORM 4 | view · |
| 8-K | 2026-06-24 | 8-K | view · |
| 8-K | 2026-06-24 | 8-K | view · |
| 4 | 2026-06-11 | FORM 4 | view · |
| 4 | 2026-06-08 | FORM 4 | view · |
| 4 | 2026-06-08 | FORM 4 | view · |
| 4 | 2026-06-08 | FORM 4 | view · |
| 4 | 2026-06-08 | FORM 4 | view · |
| 4 | 2026-06-08 | FORM 4 | view · |
| 8-K | 2026-06-05 | 8-K | view · |
| 4 | 2026-06-01 | FORM 4 | view · |
| 4 | 2026-05-13 | FORM 4 | view · |
| 10-Q | 2026-05-07 | 10-Q | view · |
| 8-K | 2026-05-07 | 8-K | view · |
| DEF 14A | 2026-04-22 | DEF 14A | view · |
| 10-K | 2026-03-24 | 10-K | view · |
| 8-K | 2026-03-24 | 8-K | view · |
| 4 | 2026-03-16 | FORM 4 | view · |
| 8-K | 2026-03-06 | 8-K | view · |
| 4 | 2026-03-05 | FORM 4 | view · |
| 4 | 2026-03-04 | FORM 4 | view · |
| 4 | 2026-03-04 | FORM 4 | view · |
| 4 | 2026-03-04 | FORM 4 | view · |
| 4 | 2026-03-04 | FORM 4 | view · |
| 4 | 2026-03-04 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-02-25 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-01-30 | FORM 4 | view · |
| 8-K | 2026-01-14 | 8-K | view · |
| 4 | 2025-12-09 | FORM 4 | view · |
| 4 | 2025-12-01 | FORM 4 | view · |
| 10-Q | 2025-11-12 | 10-Q | view · |
| 8-K | 2025-11-12 | 8-K | view · |
| 8-K | 2025-11-04 | 8-K | view · |
| 4 | 2025-10-14 | FORM 4 | view · |
| 4 | 2025-10-14 | FORM 4 | view · |
| 4 | 2025-10-14 | FORM 4 | view · |
| 4 | 2025-10-14 | FORM 4 | view · |
| 4 | 2025-09-24 | FORM 4 | view · |
| 4 | 2025-09-24 | FORM 4 | view · |
| 4 | 2025-09-02 | FORM 4 | view · |
| 10-Q | 2025-08-12 | 10-Q | view · |
| 8-K | 2025-08-12 | 8-K | view · |
| 4 | 2025-07-29 | FORM 4 | view · |
| 8-K | 2025-07-25 | 8-K | view · |
| 4 | 2025-07-09 | FORM 4 | view · |
| 8-K | 2025-07-08 | 8-K | view · |
| 4 | 2025-06-12 | FORM 4 | view · |
| 4 | 2025-06-12 | FORM 4 | view · |
| 4 | 2025-06-12 | FORM 4 | view · |
| 4 | 2025-06-12 | FORM 4 | view · |
| 4 | 2025-06-12 | FORM 4 | view · |
| 8-K | 2025-06-12 | 8-K | view · |
| 4 | 2025-06-02 | FORM 4 | view · |
About ABSI
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Options picks · ABSI
ITM + OTM ideas from the latest scanLoading…
Congress trades · ABSI
STOCK Act disclosuresLoading…
SEC filings & insiders · ABSI
EDGAR · liveLoading…
Holders · ABSI
Institutions & insider activityLoading…